Sai Life Sciences Reports 12% Revenue Growth in Q1 FY27

Sai Life Sciences recorded ₹553 crore in revenue for the first quarter of FY27, a 12% increase compared to ₹496 crore in the same period last year. The company's Contract Research Organization (CRO) business showed strong momentum, with a 26% year-on-year growth.

Reader Takeaway: Robust CRO growth faces lumpy CDMO revenue, with heavy investment in future capabilities.

What just happened

Sai Life Sciences announced its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27). Total revenue reached ₹553 crore, up 12% from Q1 FY26's ₹496 crore. The Contract Research (CRO) segment grew by 26%, while the Contract Development and Manufacturing Organization (CDMO) segment saw 6% growth.

Why this matters

The company is strategically evolving into a technology-led, multi-modality partner, investing heavily in areas like peptides and oral solid formulations. This diversification aims to capture high-value segments and enhance long-term client relationships, despite the inherent quarterly volatility in CDMO revenues.

The backstory

Sai Life Sciences has been transitioning from a small molecule CRDMO. Repeat business from existing clients accounts for over 90% of its revenue, indicating strong client retention and a focus on long-term engagements, typically 5-10 years.

What changes now

Significant capital expenditure is planned for FY27, projected between ₹1,100 crore and ₹1,300 crore, to expand capacity and develop new technology platforms. Entry into oral solid formulation for clinical supplies is expected within six months, with peptide-related spending projected under ₹300 crore by 2028.

Risks to watch

CDMO revenue performance can be unpredictable quarter-to-quarter due to the timing of large orders and shipments. The company's pipeline is also sensitive to the broader biotech funding environment, although a focus on large pharma clients aims to mitigate this.

Peer comparison

Sai Life Sciences competes in the CRO and CDMO space with other Indian and global players. Its strategic shift towards complex modalities like peptides and formulations positions it for growth in specialized, higher-margin services, differentiating it from companies solely focused on small molecules.

Context metrics (time-bound)

• Q1 FY27 Revenue: ₹553 crore (up 12% YoY)
• Q1 FY27 CRO Growth: 26% YoY
• Q1 FY27 CDMO Growth: 6% YoY
• FY27 Capex Guidance: ₹1,100 crore - ₹1,300 crore

What to track next

Investors should monitor the execution of the company's substantial capital expenditure plans and the successful ramp-up of its new peptide and formulation capabilities. The company anticipates a stronger second half of FY27 as new capacities come online.